Loar Holdings Inc. Q4 and Full Year 2025 Earnings Presentation Proprietary and Confidential 1 Forward Looking Statements & Special Notice Regarding Pro Forma and Non-GAAP Information Forward-Looking Statements This presentation includes express or implied forward-looking statements. Forward-looking statements include all statements that are not historical facts, including those that reflect our current views with respect to, among other things, our operations and financial performance. The words "anticipate ...

Core Insights - XBP Global Holdings, Inc. reported its financial results for Q3 2025, highlighting a transformative business combination with Exela BPA and a focus on growth initiatives [2][3]. Financial Performance - Reported revenue for Q3 2025 was $209.1 million, a decrease of 10.4% year-over-year, while combined pro forma revenue was $220.4 million, reflecting an 18.1% decline year-over-year [6][7]. - The gross margin on a reported basis was 22.0%, representing a 310 basis point increase year-over-year, while the pro forma gross margin was 21.9%, a 190 basis point increase year-over-year [6][7]. - Pro forma adjusted EBITDA was $24.7 million, marking a 7.4% increase year-over-year, with an adjusted EBITDA margin of 11.2%, up 260 basis points year-over-year [6][7]. Segment Results - In the Applied Workflow Automation segment, reported revenue was $189.4 million, down 14.0% year-over-year, with a gross margin of 17.7%, an increase of 170 basis points [4]. - The Technology segment saw reported revenue of $19.7 million, a 50.3% increase year-over-year, but with a gross margin of 62.9%, down 500 basis points [4]. Acquisition Details - XBP Europe finalized the acquisition of Exela BPA on July 29, 2025, issuing approximately 81.8 million shares for an equity valuation of $585.7 million, or $4.98 per share [6]. - The acquisition is expected to enhance XBP Global's corporate governance and expand its agentic AI capabilities, positioning the company for future growth [3]. Future Outlook - The CEO expressed optimism about the company's future, emphasizing initiatives in client outreach, investment in talent, and increased engagement with the investor community [3].

Core Insights - CorMedix Inc. reported Q3 2025 net revenue of $104.3 million and pro forma net revenue of $130.8 million, primarily driven by increased utilization of DefenCath by outpatient dialysis customers [4] - The company raised its full-year 2025 pro forma net revenue guidance to a range of $390 to $410 million, with fourth quarter guidance set between $115 to $135 million [4] - CorMedix achieved a net income of $108.6 million for Q3 2025, significantly improving from a net loss of $2.8 million in Q3 2024, aided by a one-time tax benefit of $59.7 million [3][4] Financial Performance - Q3 2025 net revenue was $104.3 million, with DefenCath sales contributing $88.8 million [4] - Adjusted EBITDA for Q3 2025 was reported at $71.9 million, with basic and diluted EPS at $1.42 and $1.26, respectively [4][3] - Total operating expenses for Q3 2025 were $41.7 million, a 197% increase from $14.1 million in Q3 2024, driven by non-recurring costs related to the Melinta acquisition [5] Business Developments - CorMedix completed the acquisition of Melinta Therapeutics on August 29, 2025, with integration efforts proceeding faster than expected, estimating a synergy capture of approximately $30 million [4] - The company announced a rebranding to CorMedix Therapeutics, with all employees operating under the new name [4] - CorMedix completed enrollment in the Phase III ReSPECT study for Rezzayo in October 2025, expecting top-line data in Q2 2026 [4] Cash Position - As of September 30, 2025, CorMedix reported cash and short-term investments of $55.7 million, projecting year-end cash of approximately $100 million [6][4]

Transaction Overview - Gildan will acquire all outstanding shares of HanesBrands for 0102x Gildan shares and \$080 cash per HanesBrands share[32] - The total enterprise value of the transaction is \$44 billion, implying an 89x LTM adjusted EBITDA multiple, or 63x on a fully synergized basis[32] - Upon closing, HanesBrands shareholders will own approximately 199% of Gildan shares on a non-diluted basis[32] Financial Highlights - The LTM pro forma revenue is \$69 billion, and the LTM pro forma adjusted EBITDA is approximately \$16 billion, including expected run-rate cost synergies of \$200 million[32] - Gildan expects to realize at least \$200 million of annual run-rate cost synergies within 3 years of closing, with approximately \$50 million to be realized in 2026, approximately \$100 million in 2027, and approximately \$50 million in 2028[32] - Gildan's adjusted diluted EPS CAGR over the next three years is expected to be in the low 20% range, starting from the midpoint of Gildan's 2025 adjusted diluted EPS guidance[32] Financial Position - Gildan obtained \$23 billion of committed transaction financing and expects to refinance HanesBrands' existing debt[32] - The expected closing net debt leverage ratio is 26x, with an expected net debt leverage ratio of less than 20x within 12 to 18 months post-closing, in line with the stated long-term target net debt leverage ratio of 15x – 25x[32]

Financial Performance - Q3 2025 - Revenue increased by 9.3% to $2.237 billion, compared to $2.046 billion in Q3 2024[11] - EBITDA As Defined increased by 11.5% to $1.217 billion, compared to $1.091 billion in Q3 2024[11] - Adjusted EPS increased by 6.7% to $9.60, compared to $9.00 in Q3 2024[11] - Net interest expense increased by 25.6% to $397 million, compared to $316 million in Q3 2024[11] Market Segment Performance - Q3 2025 (Pro Forma) - Commercial Transport revenue was down 8% in OEM and up 7% in Aftermarket[9] - Business Jet/Helicopter revenue was down 6% in OEM and up 5% in Aftermarket[9] - Defense OEM outpaced Defense Aftermarket growth[9] Fiscal Year 2025 Outlook - Revenue guidance midpoint is $8.79 billion, a decrease of $60 million from prior guidance[12] - EBITDA As Defined guidance midpoint is $4.725 billion, an increase of $40 million from prior guidance[12] - Adjusted EPS guidance midpoint is $36.74, an increase of $0.27 from prior guidance[12] Capital Structure - Total secured debt is $20.309 billion, with a leverage ratio of 4.4x[17] - Total net secured debt is $17.517 billion, with a leverage ratio of 3.8x[17] - Total debt is $25.188 billion, with a leverage ratio of 5.5x[17] - Total net debt is $22.396 billion, with a leverage ratio of 4.9x[17]

Financial Performance & Outlook - Q4 FY15 revenue increased by 26.1% to $809.8 million, compared to $642.2 million in Q4 FY14 [22] - Net income for Q4 FY15 increased by 24.0% to $141.7 million, compared to $114.3 million in Q4 FY14 [22] - Adjusted EPS for Q4 FY15 increased by 28.1% to $2.83, compared to $2.21 in Q4 FY14 [22] - The company anticipates FY 2016 revenues between $3.07 billion and $3.12 billion [19] - The company anticipates FY 2016 EBITDA As Defined between $1.405 billion and $1.425 billion, representing 45.7% of sales [19] Market Segment Performance - Commercial OEM revenue was up approximately 5% year-to-date [16] - Commercial Aftermarket revenue was up approximately 5% year-to-date [16] - Defense revenue was up approximately 9% year-to-date [16] Liquidity & Debt - Free cash flow for FY 2015 was $466.0 million, compared to $507.1 million in FY 2014 [24] - Cash on hand as of September 30, 2015, was $714.0 million, compared to $819.5 million in FY 2014 [24] - Total debt as of September 30, 2015, was $8.427 billion [26]

Financial Performance - TransDigm's Q4 FY2018 revenue increased by 136.5 million dollars, a 14.8% increase, from $923.9 million to $1,049.4 million [16] - Full Year FY2018 revenue increased by 766.8 million dollars, a 20.1% increase, from $3,044.3 million to $3,811.1 million [17] - Net cash provided by operating activities was $1,022.2 million in FY2018 compared to $788.7 million in FY2017 [18] - Free cash flow was $948.9 million in FY2018 compared to $717.7 million in FY2017 [18] - Adjusted EPS for FY2018 was $17.83, a 44% increase compared to $12.38 in FY2017 [17] Market Review - Q4 Commercial Aftermarket sales were up 6% [12] - Q4 Commercial OEM sales were up 1% [12] - Q4 Defense sales were up 12% [12] Fiscal Year 2019 Outlook - The industry anticipates mid to high single-digit percentage growth in commercial aftermarket [15] - The industry anticipates low to mid single-digit percentage growth in commercial OEM [15] - The industry anticipates mid to high single-digit percentage growth in defense [15]